Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
2023 · Nature Medicine · 288 citations
https://doi.org/10.1038/s41591-023-02326-3
E
Ellen Huang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
69
Papers
1.1K
Citations
15
h-index
18
i10-index
Ellen Huang is an academic researcher from Biogen (United States). The author has contributed to research in topics: Advanced Radiotherapy Techniques & Dementia and Cognitive Impairment Research & Glioma Diagnosis and Treatment. The author has an h-index of 15, co-authored 59 publications.
ORCID: 0000-0003-3902-7182Papers by this author
worksTANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease
2023 · Nature Aging · 70 citations
https://doi.org/10.1038/s43587-023-00523-w
Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy
2019 · Advances in Radiation Oncology · 21 citations
https://doi.org/10.1016/j.adro.2019.08.005
Determinants of Hypertension Among Patients With Type 2 Diabetes Mellitus in Karachi, Pakistan: A Cross-Sectional Study
2022 · Cureus · 2 citations
https://doi.org/10.7759/cureus.22157
Mortality Risk Factors for Patients With Sepsis-Induced Blood Pressure Drop: A Single-Center Retrospective Study
2022 · Cureus · 0 citations
https://doi.org/10.7759/cureus.22114
Determinants of Hypertension Among Patients With Type 2 Diabetes Mellitus in Karachi, Pakistan: A Cross-Sectional Study
2022 · Cureus · 0 citations
https://doi.org/10.7759/cureus.r52
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat